Early tumor shrinkage as a predictor of favorable outcomes in patients with advanced pancreatic cancer treated with FOLFIRINOX

There are several reports on the correlation between early tumor shrinkage (ETS) or depth of response (DpR) and survival in chemotherapies for colorectal cancer; however, few studies have investigated it in pancreatic cancer. We therefore investigated whether the ETS will predict outcomes in 59 pati...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget Ročník 7; číslo 41; s. 67314 - 67320
Hlavní autoři: Kaga, Yasuhiro, Sunakawa, Yu, Kubota, Yutaro, Tagawa, Teppei, Yamamoto, Taikan, Ikusue, Toshikazu, Uto, Yu, Miyashita, Kouichirou, Toshima, Hirokazu, Kobayashi, Kouji, Hisamatsu, Atsushi, Ichikawa, Wataru, Sekikawa, Takashi, Shimada, Ken, Sasaki, Yasutsuna
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 11.10.2016
Témata:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Disease-Free Survival
Female
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Pancreatic Neoplasms - drug therapy
Pancreatic Neoplasms - mortality
Pancreatic Neoplasms - pathology
Prognosis
Treatment Outcome
FOLFIRINOX
pancreatic cancer
early tumor shrinkage
ISSN:1949-2553
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:There are several reports on the correlation between early tumor shrinkage (ETS) or depth of response (DpR) and survival in chemotherapies for colorectal cancer; however, few studies have investigated it in pancreatic cancer. We therefore investigated whether the ETS will predict outcomes in 59 patients with advanced pancreatic cancer treated with FOLFIRINOX therapy. The association of ETS with progression-free survival (PFS) and overall survival (OS) was evaluated but also we addressed to the correlation between outcomes and DpR. ETS was defined as a reduction ≥ 20% of target lesions' diameters measured at 6 to 8 weeks from treatment start. DpR was percentage of maximal tumor shrinkage observed at the nadir diameter compared with baseline. Among 47 evaluable patients for the ETS, 12 (25.5%) patients experienced ETS. The ETS was significantly associated with better PFS (9.0 vs. 4.2 months) as well as OS (24.0 vs. 9.1 months); moreover, the association had a statistically significance for PFS but a strong trend for OS in multivariate analysis. The DpR was statistically significantly but weakly associated with OS. In conclusion, this is the first report that the early response to chemotherapy may predict favorable outcomes in patients with advanced pancreatic cancer treated with FOLFIRINOX therapy.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1949-2553
DOI:10.18632/oncotarget.12007